Skip to main navigation Skip to search Skip to main content

Kinase inhibitors in oncology What is new?

Translated title of the contribution: Kinaseinhibitoren in der Onkologie Was ist neu?
  • Technical University of Munich
  • Partnerstandort München des Deutschen Krebsforschungszentrums Heidelberg (DKFZ)

Research output: Contribution to journalArticlepeer-review

Abstract

Kinase inhibitors are now among the most important drugs in targeted therapy and are used in particular for the treatment of different tumor entities. Since many kinase inhibitors inhibit various tyrosine kinases efficiently but not specifically, they are often characterized by their versatile use in a wide variety of entities and diseases. The diverse use of this group of drugs, as well as the challenge of their side-effect profile, continues to make kinase inhibitors the subject of numerous clinical studies. The following article provides an overview of recent new approvals in the field of kinase inhibitors and shows their importance for oncological therapy.

Translated title of the contributionKinaseinhibitoren in der Onkologie Was ist neu?
Original languageGerman
Pages (from-to)540-544
Number of pages5
JournalInternist
Volume60
Issue number5
DOIs
StatePublished - May 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Kinaseinhibitoren in der Onkologie Was ist neu?'. Together they form a unique fingerprint.

Cite this